Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

Inclusion Criteria: * Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity; * Double or triple hit confirmed by pathology; * Age ≥ 65 years old; * ECOG performance status score of 0, 1, or 2; * No history of malignant tumor; no concurrent occurrence of other tumors; * Patients whose life expectancy is at least 6 months, as determined by the researcher; * The patient or their legal guardian must provide written informed consent before undergoing any special examinations or procedures in the study. * International Prognostic Index (IPI) \> 1 point. Exclusion Criteria: * There is a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ; * Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc; * Primary central nervous system lymphoma; * Left ventricular ejection fraction (LVEF) is less than or equal to 50%; * Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count \<1.5\*10\^9/L; B. Platelet count \<75\*10\^9/L; C. ALT or AST is more than twice the upper limit of normal, and AKP and bilirubin are more than 1.5 times the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal; * Other concurrent and uncontrolled medical conditions that the researcher believes will affect the patient's participation in the study. * Patients wi…